Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC. | Biomed J | 2026 | 42270077 | PubTator, text mining | PubMed |
| PRMT5 is a prognostic-related biomarker associated with the tumor immune microenvironment in lung adenocarcinoma. | Clin Transl Oncol | 2026 | 42247115 | PubTator, text mining | PubMed |
| PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma. | J Neurooncol | 2026 | 42247073 | PubTator, text mining | PubMed |
| LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. | Cell Rep | 2026 | 42234565 | PubTator, text mining | PubMed |
| Arginine methylation of human DNA topoisomerase I by PRMT5 facilitates DNA relaxation. | Nucleic Acids Res | 2026 | 42216760 | PubTator, text mining | PubMed |
| Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology. | Am Soc Clin Oncol Educ Book | 2026 | 42207998 | PubTator, text mining | PubMed |
| Affinity purification contaminants identified by cryo-EM and mass spectrometry. | Biosci Rep | 2026 | 42207602 | PubTator, text mining | PubMed |
| MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy. | Cancer Sci | 2026 | 42198893 | PubTator, text mining | PubMed |
| Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma. | Eur J Med Chem | 2026 | 42190431 | PubTator, text mining | PubMed |
| Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation. | J Med Chem | 2026 | 42172174 | PubTator, text mining | PubMed |
| Update on the Development of Targeting Arginine Methyltransferase PRMT5 in Cancer Research. | Curr Top Med Chem | 2026 | 42163734 | PubTator, text mining | PubMed |
| The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers. | J Med Chem | 2026 | 42150143 | PubTator, text mining | PubMed |
| Impact of Chromosomal Instability and Aneuploidy in Cancer Development. | Annu Rev Cancer Biol | 2026 | 42137044 | PubTator, text mining | PubMed |
| Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms. | JCO Precis Oncol | 2026 | 42133901 | PubTator, text mining | PubMed |
| MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy. | Sci Rep | 2026 | 42129334 | PubTator, text mining | PubMed |
| Inactivation of PRMT5 by PARP Inhibitors Confers High Susceptibility in MTAP-Deficient Cancers. | Cancers (Basel) | 2026 | 42122132 | PubTator, text mining | PubMed |
| Identification of METTL3 and PRMT5 as an oncogenic pair for the prognosis and therapeutic targets of colorectal cancer subtype. | Clin Epigenetics | 2026 | 42121254 | PubTator, text mining | PubMed |
| Inhibition of PRMT5 reduces angiogenesis in a corneal neovascularization model by blocking NLRP3-mediated pyroptosis. | Clin Epigenetics | 2026 | 42098764 | PubTator, text mining | PubMed |
| Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors. | Cancer Treat Rev | 2026 | 42096787 | PubTator, text mining | PubMed |
| Emerging role of protein arginine methyltransferase 5 in gastrointestinal cancer (Review). | Oncol Lett | 2026 | 42094816 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=4